Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A non-interventional study assessing Quality of life and clinical outcomes in metastatic colorectal cancer patients treated with FOLFIRI and aflibercept in Germany, Switzerland, and Austria (GSA): QoLiTrap-study

Next Previous
Search
Trial Profile

A non-interventional study assessing Quality of life and clinical outcomes in metastatic colorectal cancer patients treated with FOLFIRI and aflibercept in Germany, Switzerland, and Austria (GSA): QoLiTrap-study

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aflibercept (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms QoLiTrap

    • Most Recent Events

    • 03 Jul 2021 Results (n=1277) presented at the 23rd World Congress on Gastrointestinal Cancer.
    • 08 Jun 2021 Results assessing impact of RAS status and prior targeted therapy received (n=1277) presented at the 57th Annual Meeting of the American Society of Clinical Oncology
    • 12 Sep 2017 Interim results (data cut-off: 02 March 2017, n=576) presented at the 42nd European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top